BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeifman RJ, Palhano-Fontes F, Hallak J, Arcoverde E, Maia-Oliveira JP, Araujo DB. The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial. Front Pharmacol 2019;10:1325. [PMID: 31798447 DOI: 10.3389/fphar.2019.01325] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Yang KH, Han BH, Palamar JJ. Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults. Addict Behav 2022;132:107343. [PMID: 35525189 DOI: 10.1016/j.addbeh.2022.107343] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenwaym KT, Garel N, Beaulieu S, Kennedy SH, Lam RW, Milev R, Ravindran AV, Tourjman V, Ameringen MV, Yatham LN, Taylor V. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. Can J Psychiatry 2022;:7067437221111371. [PMID: 35975555 DOI: 10.1177/07067437221111371] [Reference Citation Analysis]
3 Lowe H, Toyang N, Steele B, Grant J, Ali A, Gordon L, Ngwa W. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders. Molecules 2022;27:2520. [DOI: 10.3390/molecules27082520] [Reference Citation Analysis]
4 Husain MI, Umer M, Mulsant BH. Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits? Expert Opin Drug Saf 2022. [PMID: 35387542 DOI: 10.1080/14740338.2022.2063274] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jones GM, Nock MK. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. J Psychopharmacol 2022;:2698811211066714. [PMID: 34983261 DOI: 10.1177/02698811211066714] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
6 Jones GM, Nock MK. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. J Psychopharmacol 2022;:2698811211058923. [PMID: 34983249 DOI: 10.1177/02698811211058923] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
7 Kelly JR, Gillan CM, Prenderville J, Kelly C, Harkin A, Clarke G, O'Keane V. Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective. Front Psychiatry 2021;12:800072. [PMID: 34975593 DOI: 10.3389/fpsyt.2021.800072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
8 Sarris J, Pinzon Rubiano D, Day K, Galvão-Coelho NL, Perkins D. Psychedelic medicines for mood disorders: current evidence and clinical considerations. Curr Opin Psychiatry 2022;35:22-9. [PMID: 34855694 DOI: 10.1097/YCO.0000000000000759] [Reference Citation Analysis]
9 Strumila R, Nobile B, Korsakova L, Lengvenyte A, Olie E, Lopez-Castroman J, Guillaume S, Courtet P. Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors. Pharmaceuticals (Basel) 2021;14:1213. [PMID: 34959614 DOI: 10.3390/ph14121213] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
10 Koslowski M, Johnson MW, Gründer G, Betzler F. Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. Curr Addict Rep 2022;9:48-58. [DOI: 10.1007/s40429-021-00401-8] [Reference Citation Analysis]
11 Kočárová R, Horáček J, Carhart-Harris R. Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential? Front Psychiatry 2021;12:661233. [PMID: 34349678 DOI: 10.3389/fpsyt.2021.661233] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
12 Campbell M, Williams MT. The Ethic of Access: An AIDS Activist Won Public Access to Experimental Therapies, and This Must Now Extend to Psychedelics for Mental Illness. Front Psychiatry 2021;12:680626. [PMID: 34290631 DOI: 10.3389/fpsyt.2021.680626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Martinotti G, Schiavone S, Negri A, Vannini C, Trabace L, De Berardis D, Pettorruso M, Sensi SL, Di Giannantonio M. Suicidal Behavior and Club Drugs in Young Adults. Brain Sci 2021;11:490. [PMID: 33921484 DOI: 10.3390/brainsci11040490] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Sarris J, Perkins D, Cribb L, Schubert V, Opaleye E, Bouso JC, Scheidegger M, Aicher H, Simonova H, Horák M, Galvão-coelho NL, Castle D, Tófoli LF. Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers. Journal of Affective Disorders Reports 2021;4:100098. [DOI: 10.1016/j.jadr.2021.100098] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
15 Earleywine M, Ueno LF, Mian MN, Altman BR. Cannabis-induced oceanic boundlessness. J Psychopharmacol 2021;35:841-7. [PMID: 33779383 DOI: 10.1177/0269881121997099] [Reference Citation Analysis]
16 Ross S, Agin-Liebes G, Lo S, Zeifman RJ, Ghazal L, Benville J, Franco Corso S, Bjerre Real C, Guss J, Bossis A, Mennenga SE. Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS Pharmacol Transl Sci 2021;4:553-62. [PMID: 33860185 DOI: 10.1021/acsptsci.1c00020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
17 Zeifman RJ, Singhal N, Breslow L, Weissman CR. On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review. ACS Pharmacol Transl Sci 2021;4:436-51. [PMID: 33860173 DOI: 10.1021/acsptsci.1c00024] [Reference Citation Analysis]
18 Dos Santos RG, Bouso JC, Rocha JM, Rossi GN, Hallak JE. The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges. Risk Manag Healthc Policy 2021;14:901-10. [PMID: 33707976 DOI: 10.2147/RMHP.S300656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
19 Galvão-Coelho NL, Marx W, Gonzalez M, Sinclair J, de Manincor M, Perkins D, Sarris J. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology (Berl) 2021;238:341-54. [PMID: 33427944 DOI: 10.1007/s00213-020-05719-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
20 Zeifman RJ, Singhal N, Dos Santos RG, Sanches RF, de Lima Osório F, Hallak JEC, Weissman CR. Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial. Psychopharmacology (Berl) 2021;238:453-9. [PMID: 33118052 DOI: 10.1007/s00213-020-05692-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
21 Zeifman RJ, Wagner AC, Watts R, Kettner H, Mertens LJ, Carhart-Harris RL. Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation. Front Psychiatry 2020;11:782. [PMID: 32903724 DOI: 10.3389/fpsyt.2020.00782] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]